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Migraine-like Headache in a Patient with Complement 1 Inhibitor 
Deficient Hereditary Angioedema
We report on an angioedema patient with a genetic defect in complement 1 inhibitor, 
manifesting migraine-like episodes of headache, effective prophylaxis with Danazol, and 
triptan for a treatment of acute clinical episode. The patient was 44-yr-old Korean man 
with abdominal pain and headache, who was brought into the Emergency Department of 
Seoul National University Hospital, Seoul. He suffered from frequent attacks of migraine-
like headache (3-7 per month), pulsating in nature associated with nausea. Severities were 
aggravated by activity and his headache had shown recent progression with abdominal 
pain. No remarkable findings were observed on radiologic examination, brain magnetic 
resonance images and intracranial and extracranial magnetic resonance angiography. 
Danazol 200 mg every other day was subsequently used. Following administration of 
Danazol, symptoms showed improvement and the patient was discharged. While taking 
Danazol, the migraine-like episodes appeared to be prevented for about 2 yr. At the eighth 
month, he suffered a moderate degree of migraine-like headache; however, administration 
of naratriptan 2.5 mg resolved his problem. A case of genetic defect of C1-INH deficiency 
presented with headache episodes, and was controlled by Danazol and triptan. It suggests 
that pathogenic mechanism of headache in hereditary angioedema may be mediated by 
the neurogenic inflammatory-like physiology of migraine.
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INTRODUCTION
Angioedema is clinically characterized by episodes of marked 
edema involving the skin, gastrointestinal, and other organs. 
There are various forms of acquired and hereditary angioedema 
(HAE). Classic HAE is associated with a deficiency of the Com-
plement 1 inhibitor (C1-INH), C1 esterase. Deficiencies of this 
protein allow unchecked activation of the classic complement 
pathway (1). C1-INH also inhibits components of the fibrinolytic, 
clotting, and kinin pathways. Activation of the kinin system in-
creases blood bradykinin, an inflammatory mediator responsi-
ble for capillary leakage. Bradykinin excites primary sensory neu-
rons and provokes the release of neuropeptides such as substance 
P, neurokinin A, and calcitonin gene-related peptide (2). 
  In a previous report of headache and HAE, headache were 
reported in 18 of 209 patients. The severe headache lasted for 4 
hr to 4 days, accompanied by other signs; feeling of pressure in 
the head or eyes, visual disturbances, giddiness, disorders of 
balance, ataxia, impaired orientation, vomiting, or decrease in 
physical and mental powers. Headache may be the troublesome 
symptom of HAE. Thus, all patients reported that analgesics were 
not effective. Five patients received C1-INH concentrate, which 
was effective in all treated episodes. Although they presented to 
be similar to migraine episodes, however, some clinical features 
typical for migraine were lacking. The prompt response to C1-
INH concentrate has provided a further argument that these 
headache episodes are symptoms of HAE (3). 
  The first drugs used in treatment of HAE patients were andro-
gens and their attenuated derivatives. High doses of these drugs 
can cause a significant increase in C1 inhibitor plasma levels (4). 
Before development of effective therapy, the mortality rate was 
20%-30%. Although preventable and treatable, the complica-
tions of this disease do not respond well to the usual therapies 
for angioedema; therefore, establishment of the correct diagno-
sis is critical. 
  Several theories regarding the migraine mechanism have been 
proposed. Vasodilation theory of migraine, originally proposed 
in 1938, focused on vasodilatation as the predominant causative 
factor in development of migraine pain. However, cerebral vaso-
dilatation is not temporally correlated with migraine pain using 
transcranial Doppler, PET, or fMRI; therefore, this theory is not 
uniformly supported (5-7). According to the neurogenic inflam-
mation theory of migraine, release of inflammatory neuropep-
tides, like substance P, neurokinin A and CGRP from the trigem-Chung J-Y, et al.  •  Headache in Hereditary Angioedema
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inal sensory afferent onto the dura can act on vascular tissue to 
cause the components of neurogenic inflammation; vasodila-
tion, plasma protein extravasation in the surrounding area, en-
dothelial cell changes, platelet aggregation and subsequent re-
lease of serotonin and other mediators, white cell adhesion and 
subsequent inflammation (8). Vasoconstrictive acute therapeu-
tic agents like ergotamines and triptan also inhibit release of in-
flammatory neuropeptides (9). 
  Therefore, it can be postulated that C1-INH deficiency inacti-
vates kinin systems that increase bradykinin. This can provoke 
the release of inflammatory neuropeptides which mediate neu-
rogenic inflammation of migraine headache.
  We report on a patient with a genetic defect in Complement 1 
inhibitor, manifesting migraine-like episodes of headache, effec-
tive prophylaxis with Danazol, and triptan for a treatment of acute 
clinical episode. 
 
CASE DESCRIPTION
A 44-yr-old man was brought to the Emergency Department 
complaining of abdominal pain and headache on October 8, 
2009. The patient reported abdominal pain, anorexia, and a se-
vere right temporal pulsating headache for three days. He had 
been diagnosed as hereditary angioedema (HAE) with deficien-
cy of C1 esterase inhibitor (C1INH). There was family history of 
HAE in sister, uncle and cousin. Episodic attacks of headache 
developed 4 yr ago. It was unilateral, either right or left, or of a 
bilateral pulsating nature. Headache was aggravated by activity 
and associated with nausea. Conjunctival injection or rhinor-
rhea was not associated. He denied any visual or other sensory 
prodromal symptoms before the onset of headache. There had 
been moderate severity of headache episodes three to seven 
times per month. Occasionally, he suffered from severe attacks 
of headache once or twice a year. No remarkable findings were 
observed on radiologic examination including computed tomog-
raphy in the abdomen. Brain magnetic resonance image and 
intracranial and extracranial magnetic resonance angiography 
did not show any significant abnormalities (Fig. 1). The level of 
complement C3 was 218 mg/dL and C4 was 7 mg/dL when he 
had visited emergency room. Danazol 200 mg every other day 
was medicated. While taking Danazol, the migraine-like attack 
was not happened for 23 months. At the 8th month, he suffered 
a moderate nature of migraine-like headache, when naratriptan 
2.5 mg was administered. His headache resolved within 2 hr and 
no further attach thereafter. The case report was approved by 
the institutional review board in Seoul National University Hos-
pital. Informed consent was exempted by the board.
 
Fig. 1. Brain MRI and MR angiography of this patient. (A) T1-weighted saggital magnetic resonance image shows 
no significant brain parenchymal abnormality. There is no evidence of subdural fluid collection or other mass le-
sion. (B) T2-weighted axial scan shows symmetric apprearence of cerebral hemisphere without remarkable find-
ings in suprasellar cistern. (C) Intracranial vessels including, internal carotid arteries, middle cerebral arteries 
and its bifurcation, anterior cerebral arteries, vertebrobasilar arteries do not show any stenosis or occlusion. (D) 
Neck vessels, subclavian artery, common carotid arteries with bifurcation and origin of bilateral vertebral arter-
ies are within normal limit.
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DISCUSSION
We report on a patient with a genetic defect in Complement 1 
inhibitor, associated with migraine-like headache. Danazol, a 
synthetic 17 alpha-alkylated androgen derivative has been used 
for the treatment of HAE (10). It has been also effective for the 
recurrence of headache episode. 
  In this case, Danazol administration could prevent symptoms 
or signs of HAE including severe headache. The headache was 
also prevented for up to 23 months. The mechanism of Danazol 
in HAE has been suggested that high doses can cause a signifi-
cant increase in C1 inhibitor plasma levels (4). It then inhibit the 
kinin system, which reduces bradykinin, and thus resulting in 
decreased inflammatory peptide (2). These signaling cascades 
also overlap with that of neuroinflammatiory roles in the patho-
physiology of migraine. 
  Triptans are agonists of serotonin (5-HT)1B and 5-HT1D recep-
tors and have been used for treatment of migraines that do not 
respond to NSAIDs (11-13). Triptan also inhibit the release of 
inflammatory neuropeptides (9). In this patient, Naratriptan 
(triptan drug) was effective when headache episode appeared. 
However, response to the naratriptan was not enough to confirm 
the diagnosis of migraine, or efficacy of other drugs. Neither it 
excludes other possibilities of multiple mechanisms in migraine 
pathogenesis. However, present finding with response to narat-
riptan can suggest that headache associated with HAE can be 
interpreted as migraine-like headache, possibly involving patho-
physiology in neurogenic inflammation. Reported efficacy C1-
INH concentrate also supported the neuroinflammatory mech-
anism of headache in patients with HAE, which may account 
for the efficacy of Danazol in this case. However, this is only one 
case-based observation, further evidences are warranted to be 
accumulated.
  It is unknown whether Danazol can be used for the prophy-
laxis of migraine. Reports on 55 Vietnamese immigrants with 
headache showed that there was decreased level of C1 esterase 
inhibitor. Although all of them did not have angioedema, Dan-
azol treatment improved headache, and these patients may rep-
resent a form of androgen-responsive headache, which is asso-
ciated with low levels of C1INH (14). Incidence of headache or 
migraine in HAE is lower than that of migraine in general popu-
lation. It can be assumed that Danazol treatment for HAE may 
likely reduce the attack of headache in patient comorbid with 
migraine headache. Gender-difference with more female pre-
ponderance can also be considered to be associated with this 
hormonal effect, which remains to be explored (15). 
  Taken together, a case of genetic defect of C1-INH deficiency 
presented with migraine-like headach, and was controlled by 
Danazol and triptan, suggesting the neurogenic inflammatory 
mechanism in migraine physiology.
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